Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds
Source: SeekingAlpha
2025-10-29 14:02:12 ET
I wrote my initial thesis on Dr. Reddy’s Laboratories ( RDY ) in January 2025. At that time I rated RDY a strong buy owing to its lucrative valuation compared to industry peers. As the market does not offer a free lunch, this discount was also backed by a solid headwind primarily stemming from the expected revenue cliff-off from the patent expiration and subsequent competition for one of the star drugs, Revlimid....
Read the full article on Seeking Alpha
For further details see:
Dr. Reddy's: Underappreciated Future Amid Exaggerated Headwinds
Dr. Reddy's Laboratories Ltd
NASDAQ: RDY
RDY Trading
-1.43% G/L:
$14.16 Last:
1,384,425 Volume:
$14.32 Open:
RDY Latest News
February 20, 2026 10:57:00 am
Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
RDY Stock Data
$11,719,925,601
612,073,010
N/A
98
N/A
Pharmaceuticals
Healthcare
IN
Hyderabad
